Clobazam (Onfi) vs Staccato Alprazolam

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Clobazam (Onfi)

Marketed by Lundbeck LLC and partners

Approved in Epilepsysmall molecule
Reliable signal

NCT00518713 · Phase 3 · completed

The study randomly assigned 238 participants to low-, medium-, or high-dose clobazam or placebo, with participants, care providers, and investigators masked to treatment. Its clinical primary endpoint—percent reduction in drop seizures—was statistically better than placebo for all three doses, supporting a strong evidence grade.

Reported efficacy

Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) (met)

Result source: NCT00518713

Staccato Alprazolam

Developed by UCB and partners

Phase 3 in Epilepsysmall molecule
Reliable signal

NCT03478982 · Phase 2 · completed

The study randomized participants to Staccato alprazolam or matching placebo and was described as quadruple-blind, with 156 participants enrolled and 38, 38, and 40 participants in the evaluable 1.0-mg, 2.0-mg, and placebo groups, respectively. Its primary clinical endpoint—seizure cessation within 2 minutes without recurrence for 2 hours—was statistically significantly better with both alprazolam doses than with placebo.

Next expected readout: March 2027 · NCT05077904 (registry estimate)

Reported efficacy

Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours (2 hours post-dosing on dosing day): 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) (met)

Result source: NCT03478982

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointClobazam (Onfi)Staccato Alprazolam
Seizure frequency, % change—Not reported—Trial running · NCT05076617
50% responder rate—Not reported—Trial running · NCT05076617
Seizure freedom—Not reported—Trial running · NCT05076617

Seizure frequency, % change

Clobazam (Onfi)
—Not reported
Staccato Alprazolam
—Trial running · NCT05076617

50% responder rate

Clobazam (Onfi)
—Not reported
Staccato Alprazolam
—Trial running · NCT05076617

Seizure freedom

Clobazam (Onfi)
—Not reported
Staccato Alprazolam
—Trial running · NCT05076617
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clobazam (Onfi): 4 of 4 rows · Staccato Alprazolam: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClobazam (Onfi)Staccato Alprazolam
Dropout rate
30.5%high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
13.8%low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
27.4%medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
29.6%
NCT01160770 · Phase 3 · monotherapy
10%
NCT03371836 · Phase 4 · registry result, not featured evidence
0%2.0 mgb
NCT03478982 · Phase 2
show 2 more results
0%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Discontinued due to AEs
—high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
—low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
—medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
3.7%
NCT01160770 · Phase 3 · monotherapy
—
NCT03371836 · Phase 4 · registry result, not featured evidence
—2.0 mgb
NCT03478982 · Phase 2
show 2 more results
—1.0 mg
NCT03478982 · Phase 2
—1.0 mg
NCT03478982 · Phase 2
Serious AEs
8.5%high dosea
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 4 more results
5.2%low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
9.7%medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
43.1%
NCT01160770 · Phase 3 · monotherapy
—
NCT03371836 · Phase 4 · registry result, not featured evidence
0%2.0 mgb
NCT03478982 · Phase 2
show 2 more results
2.6%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Most frequent reported AEs
high dosea
somnolence 25.4% (placebo 11.9%)
lethargy 15.3% (placebo 5.1%)
aggression 13.6% (placebo 5.1%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
show 3 more results
low dose
pyrexia 17.2% (placebo 3.4%)
somnolence 15.5% (placebo 11.9%)
lethargy 10.3% (placebo 5.1%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
medium dose
somnolence 24.2% (placebo 11.9%)
drooling 12.9% (placebo 3.4%)
upper respiratory tract infection 12.9% (placebo 10.2%)
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3
upper respiratory tract infection 28.1%
pyrexia 18%
somnolence 16.9%
NCT01160770 · Phase 3 · monotherapy
2.0 mgb
cough 18.4% (placebo 0%)
dysgeusia 10.5% (placebo 2.5%)
somnolence 10.5% (placebo 2.5%)
NCT03478982 · Phase 2
show 2 more results
1.0 mg
somnolence 18.4% (placebo 2.5%)
dysgeusia 15.8% (placebo 2.5%)
cough 10.5% (placebo 0%)
NCT03478982 · Phase 2
1.0 mg
cough 12.5% (placebo 0%)
dysmenorrhoea 12.5% (placebo 0%)
gastroenteritis viral 12.5% (placebo 0%)
NCT03478982 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clobazam (Onfi)

Drop Seizure -41.2% (n=53) vs -12.1% (n=57) placebo @ 12wklow dose
percent change · % of baseline
Maintenance
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 41.2 Percent Reduction as posted
show 11 more results
-49.4% (n=58) vs -12.1% (n=57) placebo @ 12wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 49.4 Percent Reduction as posted
-68.3% (n=49) vs -12.1% (n=57) placebo @ 12wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 68.3 Percent Reduction as posted
-47.8% (n=53) vs -18.6% (n=57) placebo @ 4wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 47.8 Percent reduction as posted
-58.9% (n=58) vs -18.6% (n=57) placebo @ 4wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 58.9 Percent reduction as posted
-71% (n=49) vs -18.6% (n=57) placebo @ 4wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 71 Percent reduction as posted
-44.1% (n=52) vs -21.1% (n=47) placebo @ 8wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 44.1 Percent reduction as posted
-38.8% (n=53) vs -21.1% (n=47) placebo @ 8wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 38.8 Percent reduction as posted
-64.9% (n=44) vs -21.1% (n=47) placebo @ 8wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 64.9 Percent reduction as posted
-31.8% (n=51) vs 0.1% (n=44) placebo @ 12wk*low dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 31.8 Percent reduction as posted
-56% (n=46) vs 0.1% (n=44) placebo @ 12wk*medium dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 56 Percent reduction as posted
-68% (n=42) vs 0.1% (n=44) placebo @ 12wk*high dose
NCT00518713 · Phase 3 · monotherapy · Epilepsy, Lennox-Gastaut Syndrome · phase 3 · converted to % from 68 Percent reduction as posted
CGI-I 2 score
absolute value · score
No placebo or comparator arm
NCT03371836 · Phase 4 · registry result, not featured evidence

Staccato Alprazolam

Seizure Cessation 2min no Recurrence 2 h 65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
62.5% (n=8) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Rescue Medication Use 7.9% (n=38) vs 7.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
0% (n=8) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
15.8% (n=38) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Secondary Generalization 0% (n=38) vs 0% (n=40) placebo @ 0.14wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
12.5% (n=8) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2
0% (n=38) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clobazam (Onfi)'s landscape · Staccato Alprazolam's landscape